@article {BjornsonPA3625, author = {Candice Bjornson and Parco Chan and Abby Li and Bosco Paes and Krista Lanctot and Ian Mitchell}, title = {Palivizumab prophylaxis for respiratory syncytial virus (RSV) in infants with cystic fibrosis (CF) and respiratory illness hospitalizations}, volume = {46}, number = {suppl 59}, elocation-id = {PA3625}, year = {2015}, doi = {10.1183/13993003.congress-2015.PA3625}, publisher = {European Respiratory Society}, abstract = {Background: RSV in infants with CF has significant morbidities.Objectives: To evaluate effectiveness and safety of palivizumab RSV prophylaxis in infants with CF.Methods: Data on respiratory illness and RSV hospitalizations(RIH and RSVH) were collected in infants \<2 years with CF in Alberta, Canada from 2000-2009. Outcomes in palivizumab-treated(PVZ) vs untreated(UPVZ) infants were compared with chi-square, Fisher{\textquoteright}s exact, Mann-Whitney{\textquoteright}s U or Student{\textquoteright}s t-tests, and Poisson regression for factors influencing hospitalization.Results: 130 infants(43 PVZ;87 UPVZ) were included. PVZ group had more infants diagnosed by newborn screen(60.5\% vs. 23.0\%,χ2=17.7,df=1,p\<0.005) and with failure to thrive(FTT) (55.8\% vs. 37.9\%,χ2=3.7,df=1,p=0.05) than UPVZ. 49 infants had a total of 82 RIH and 6 infants had 8 RSVH. PVZ treatment did not predict number of RIH(Incidence Rate Ratio [IRR]=1.1,95\%CI=0.6-1.8,p=0.8), after adjustment for CF diagnosis method and FTT, while FTT itself was a significant predictor(IRR=1.7,95\%CI=1.1-2.7,p=0.03). RSVH was not predicted by PVZ treatment(IRR=0.3,95\%CI=0.04-2.84,p=0.3), method of CF diagnosis(IRR=0.4,95\%CI=0.04-3.32,p=0.4) nor FTT(IRR=1.5,95\%CI=0.4-6.0,p=0.5). For RSVH, there were no differences between groups in days of intensive care(mean 5.0{\textpm}5.7,n=2), O2 use(mean 6.5{\textpm}0.7,n=2) or total length of stay(mean 34.5{\textpm}36.1,n=6,U=0.00,p=0.3). There were no serious adverse events related to PVZ.Conclusions: There were no differences in RSVH and RIH or morbidities between groups. Though sample size is one of the largest reported, power may be insufficient to detect differences. Further larger prospective studies are needed.}, issn = {0903-1936}, URL = {https://erj.ersjournals.com/content/46/suppl_59/PA3625}, eprint = {https://erj.ersjournals.com/content}, journal = {European Respiratory Journal} }